Professeur, Faculté de médecine et des sciences de la santé
FMSS Département de médecine
(2015) Localisation et implication des phospholipases A2 cytosolique et sécrétée dans le contrôle de l’ostéoclastogénèse et des fonctions ostéoclastiques chez l’humain. [Implication of cytosolic and secreted phospholipases A2 in the control of osteoclastogenesis and human osteoclasts’ functions]. Doctorate (Philosophiae Doctor in Pharmacology). Université de Sherbrooke.
(2014) Post-doctorate. Université de Sherbrooke.
(2011) Post-doctorate (Internal medicine). Université de Sherbrooke.
(2011) Doctorate (Medicinae Doctor). Université de Sherbrooke.
(2009) Certificate (3rd cycle Enrichment Microprogram in Research Skills). Université de Sherbrooke.
(2007) Master's non-Thesis (Master in Pharmacology). Université de Sherbrooke.
(2005) Bachelor's (Bachelor’s Degree in Pharmacology). Université de Sherbrooke.
Research Associate (Immunology and Epigenetics). Ragon Institute of MGH, MIT and Harvard.
Fellow of the Royal College of Physicians of Canada. Royal College of Physicians and Surgeons of Canada.
NGS Data Analysis Course. Harvard School of Public Health.
Training in bone biopsy and histomorphometry. Centre hospitalier de l'université de Montréal.
Training in optical immunology. Hôpital Maisonneuve-Rosemont.
(2019) Clinician-scientist - Rheumatologist. Université de Sherbrooke.
(2016) Lecturer for the General Pharmacology class (PHR504). Université de Sherbrooke.
Auto-Immune Diseases, Arthritis / Osteo-Arthritis, Bone Diseases, Diseases of the Immune System, Molecular Genetics.
Rheumatology, Pharmacology, Immunology, Genetics, Molecular Biology.
Immunology, Epigenetics, IgG4 related disease, Inflammatory arthritis, Primary Immunodeficiency, Memory B cells, Bone metabolism, Osteoclast differentiation and metabolism.
I am interested in elucidating how immune cell dysfunction leads to the chronicity of rheumatologic diseases and end organs damages. This endeavor lead me to be part of a global effort aiming at characterizing the antigen(s) driving chronic immune activation and plasmablast activation in IgG4-RD. We were able to identify new subsets of auto-reactive activated B cells infiltrating tissu and are currently performing extensive immunophenotyping, repertoire analysis and chromatin characterization to understand their functions and ontology. I am also working with Dr Jocelyn Farmer, on her cohort of more then 180 patients with CVID, to identify, using whole exome sequencing, new monogenic causes of CVID. We then use those discrete genetic alteration as model to understand the fundament of normal lymphocyte development. We are also using the subset of CVID patients developping auto-immune condition to ask how the monogenic defects that we identify were able to lead to a breach in tolerance.
Oui
Anglais, Français, Espagnol (castillan)
Les informations disponibles dans la base de données Expertus sont tirées du CV commun canadien.